Introduction {#s1}
============

Allergic rhinitis (AR) is an inflammatory disorder of the nasal epithelium. Anterior and posterior rhinorrhea, nasal congestion, sneezing, and itching are typical clinical symptoms, which are reversible spontaneously or in response to therapy ([@B14]).

AR is not considered to be the most serious medical condition compared with other respiratory diseases. However, patients with AR have a reduced quality of life, lack of or worsened quality of sleep, cognitive function impairment, irritability, and fatigue, especially during peak pollen season ([@B2]). The most common form of AR is caused by exposure of sensitized patients to allergens such as house dust mites, grass pollen, tree pollen, weed pollens, cat and dog fur, and mold ([@B14]).

The phenotypes of this disease appear to actively change, with about 50--70% of patients suffering from mixed rhinitis (non-AR and AR) and approximately 10--20% suffering from the pharmacologically resistant phenotype. AR with localized nasal allergic response in the absence of systemic atopy has also been identified ([@B26]).

Standard treatment of AR includes the combination of oral antihistamines and glucocorticoids (GCs), which may not provide sufficient relief from symptoms; thus, novel therapies are needed ([@B36]). In recent years, various AR phenotypes caused by non-T helper 2 (Th2) cell-mediated inflammation have been identified. Therefore, it is important to develop more effective drugs with different mechanisms of action such as inhibition of Janus kinase, phosphodiesterase (PDE), and chemoattractant receptor homologous molecule of Th2 cells ([@B16]).

PDEs are responsible for the hydrolysis of intracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which have emerged as novel therapeutic targets. PDE inhibitors allow the elevation of cAMP and cGMP, which leads to a variety of cellular effects such as relaxation of airway smooth muscle and inhibition of cellular inflammation. Special attention has been paid to PDE4 inhibitors, which are potent anti-inflammatory agents that have shown encouraging results in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Their potential in the management of upper airway diseases has also been suggested. This review summarizes current evidence on the beneficial as well as harmful effects of the clinical use of PDE4 inhibitors in allergic rhinitis/rhinosinusitis ([@B8]).

Definition and Epidemiology of AR {#s2}
=================================

AR is clinically defined as a symptomatic disorder of the nose induced after allergen exposure by immunoglobulin E (IgE)-mediated inflammation of the nasal membranes ([@B10]). AR is an extremely common disease that persists throughout life ([@B2]) and occurs very frequently. Real-time data are difficult to interpret. Statistics only show physician-diagnosed AR, but the number of patients suffering from AR is a bit higher ([@B33]). During the last 20--30 years, the prevalence of allergic diseases has increased ([@B16]). The prevalence of self-reported AR has also increased and is approximately 2%--25% in children and 1% to more than 40% in adults. The prevalence of confirmed AR in adults oscillates in Europe from 17% to 28.5% ([@B2]), meaning that 100--150 million individuals in Europe suffer from AR ([@B26]). In the United States, 10--30% of the population has been diagnosed with AR ([@B7]). In Asia, AR affects a large part of the population, from 27% in South Korea to 32% in the United Arab Emirates ([@B5]). The incidence of AR seems to be comparable worldwide. AR is frequently associated with asthma; 15--38% of patients with AR have asthma and nasal symptoms are present in 6--85% of asthmatic patients. Thus, AR is a risk factor for asthma and successful management of AR can improve asthma symptoms ([@B2]).

Pathophysiology of AR {#s3}
=====================

As aforementioned, the most causal antigens for AR are inhalant allergens such as house dust mites, animal dander, and pollen. Many allergens have protease activity and are able to impair the epithelial barrier and penetrate into nasal mucosa. Allergen-specific Th2 cells are produced in patients with AR, whereas allergen-specific Th1 cells are produced in healthy individuals ([@B22]). The results of long-term studies have shown that all allergic diseases are primarily characterized by enhanced Th2 pathway activation, increased serum levels of IgE, blood eosinophil count, and allergen reactivity ([@B41]). However, in the last several years, the concept of AR has shifted from increased Th2 signaling and downstream inflammation to disease phenotypes with non-Th2 mediated inflammation. AR is a largely heterogenous group of airway diseases, and as such, research should not only focus on immunosuppressive agents (e.g., corticosteroids) but should also include targeted immunomodulatory pathways ([@B22]).

Basophil cells produce cytokines such as interleukin 4 (IL-4) and thymic stromal lymphopoietin in response to allergens with protease activity, and may contribute to Th2 differentiation ([@B34]). Th2 cells produce IL-4/IL-13 and express CD40 ligand, which are responsible for converting B cells to IgE-producing B cells ([@B22]). Inhalation of allergens by sensitized patients is followed by antigen passing through the epithelial tight junctions in the nasal mucosa and binding to IgE receptors on the surface of mast cells in the nasal mucosa. Chemical mediators such as histamine and prostaglandins are released. Histamine increases paracellular permeability by regulating tight junctions through coupling with H1 receptors ([@B22]). Interactions among chemical mediators, sensory nerve terminals, and blood vessels are responsible for the early phase of AR (sneezing, rhinorrhea, nasal congestion) ([@B11]). Late-phase inflammation develops within 6--10 h after allergen stimulation ([@B22]).

Dysregulation of dendritic cells (DCs) plays an important role in the pathogenesis of AR. Understanding DC biology and its functions in physiologic and pathologic conditions may provide an understanding of the role of DCs in the initiation and perpetuation of inflammatory sinonasal diseases, and also lead to the development of potentially novel therapeutic strategies targeting DCs ([@B3]). DCs influence inflammation and adaptive responses of the body by releasing pro-inflammatory cytokines and other mediators. They are antigen-presenting cells (APCs) able to polarize T effector cells.

Activation of the cytotoxic activity of natural killer and CD8^+^ T cells protects against intracellular pathogens, but can also lead to tissue injury. DCs produce IL-23, and together with IL-6 and IL-1β, are involved in the expansion of Th17 cells, which are responsible for strong pro-inflammatory responses against extracellular pathogens, possibly leading to chronic inflammation and autoimmune diseases ([@B13]). Thus, for novel therapeutic strategies, it is important to focus on pathological conditions characterized by the expansion of Th1 and/or Th17 responses ([@B13]).

Therapy {#s4}
=======

The primary non-pharmacological strategy in AR management is avoiding allergens and irritants ([@B28]). In relation to the elimination of allergens, topical saline irrigations help to reduce symptoms of AR when used alone or together with other drugs ([@B12]).

As first-line therapy for AR, GCs and antihistamines administered orally or intranasally are used. GCs have become a clinical mainstay for the suppression of numerous inflammatory and autoimmune diseases. They reduce the infiltration of inflammatory cells into the nasal mucosa, maturation of immunocompetent cells, cytokine production, and mediator release by mast cells ([@B17]). They also inhibit histamine release, induce apoptosis of eosinophils, and reduce the recruitment of APCs ([@B22]). Inhibition of B cells through GCs is limited, but GCs are able to inhibit class-switching to IgE in the nasal mucosa ([@B37]). GCs are also known as anti-inflammatory drugs that affect nasal constitutive, epithelial, vascular endothelial cells, and glands ([@B22]). GCs signal through genomic and non-genomic pathways ([@B27]). The classic, genomic actions of GCs are mediated through a single GC receptor (GR) with many isoforms, which expands the heterogeneity of hormonal signaling. GRs are expressed throughout the body and are localized in the cytoplasm of target cells. The main anti-inflammatory effects of GC are based on their ability to inhibit the transcription of cytokine and chemokine genes participating in inflammation ([@B24]).

Three generations of antihistamines that specifically block the effects of histamine on histaminergic receptors are available. First-generation oral antihistamines such as cyproheptadine are no longer recommended, because of their sedative and anticholinergic effects. Second-generation antihistamines such as loratadine or rupatadine lead to good improvements in symptoms without side effects to the central nervous system. They are rapid and well tolerated for the symptomatic treatment of AR ([@B14]).

The combination of oral antihistamines and intranasal corticosteroids is a reasonable choice because of the significantly faster onset of treatment effects. However, the combination of intranasal antihistamines and intranasal corticosteroids does not alleviate symptoms as well as the combination of oral antihistamines with intranasal corticosteroids ([@B2]).

During the above-mentioned long-term therapy, some side effects can occur such as atrophy of the nasal mucosa or systemic side effects, especially in children ([@B9]). Antihistamines can cause drowsiness or prolongation of the QT interval on electrocardiogram ([@B29]). Common pharmacological treatment with intranasal steroids, oral or intranasal antihistamines does not completely relieve the symptoms of AR ([@B36]). This is why more specific substances for disease control are needed.

PDES as a Therapeutic Target {#s5}
============================

PDEs are a group of enzymes consisting at least of 11 members that cause hydrolysis and subsequent inactivation of cAMP and cGMP serving as intracellular second messengers ([@B16]; [@B21]). They modulate many cellular functions such as contractility of the myocardium, airway and vascular smooth muscle tone, platelet aggregation, and the release of inflammatory mediators ([@B35]). PDE3, PDE4, PDE5, and PDE7 isoforms are the most well studied selective PDEs in relation to immune responses in the respiratory system ([@B20]).

PDE4 is the major cAMP-metabolizing enzyme expressed inside the inflammatory cells. The PDE4 family in mammals consists of four subfamilies, encoded by four genes (*PDE4A, PDE4B, PDE4C*, and *PDE4D*). *PDE4A*, *PDE4B*, and *PDE4D* are expressed by neutrophils, eosinophils, B cells, T cells, DCs, monocytes, and macrophages. Expression of *PDE4C* is typically minimal or absent ([@B8]). Expression is triggered by epithelial damage, microbial invasion, and allergen sensitization. Its inhibition is a promising target for suppressing inflammatory responses ([@B8]) as was demonstrated for roflumilast in an animal model of acute lung injury ([@B19]). PDE4 inhibitors are well-characterized pharmaceutical agents with a broad range of anti-inflammatory activities also in various inflammatory conditions including allergic diseases ([@B16]).

As aforementioned, PDE4 inhibitors may serve as potential therapeutic agents for various respiratory diseases, as well as for non-Th2 mediated AR. These effects have been evaluated *in vitro* and in animal models of allergic asthma. Their anti-inflammatory activity results from blocking the degradation of cAMP in lymphocytes, eosinophils, neutrophils, and monocytes, leading to the attenuated release of histamine and leukotrienes as well as the release of several cytokines including IL-4, IL-5, IL-10, and granulocyte-macrophage colony-stimulating factor ([@B29]). Inhibition of PDE4 increases accumulation of intracellular cAMP and helps to balance anti- and pro-inflammatory effects. PDE4 inhibitors such as apremilast, roflumilast, and crisaborole have been tested in clinical trials for various inflammatory diseases. Apremilast is now approved for the treatment of adults with moderate to severe plaque psoriasis and/or psoriatic arthritis ([@B25]). Roflumilast has shown initial efficacy for treating asthma, COPD, and asthma-COPD overlap ([@B40]). Based on phase III trials, crisaborole is considered an efficacious topical agent with a safety profile and limited systemic exposure. It is promising candidate for the treatment of atopic dermatitis ([@B39]).

PDE4 inhibitors, such as roflumilast, are able to suppress various inflammatory responses ([@B23]; [@B38]). A clinical study with oral doses of roflumilast in patients with COPD took place in III trial phases demonstrated its anti-allergic and anti-inflammatory benefits ([@B23]). Roflumilast is now approved for treatment of COPD ([@B15]) and is recommended at a dose of 500 μg once daily. Many more studies have tested the effects of roflumilast on COPD than on AR ([@B6]).

The efficacy and safety profile of roflumilast shows that it leads to more side effects than other PDE4 inhibitors administered intranasally in patients with COPD. The most frequent side effects are nausea, diarrhea, appetite loss and weight loss, abdominal pain, headache, gastrointestinal, and sleep disturbance. These side effects limit the use of roflumilast in clinical practice. Therefore, real-world studies on the clinical use of this PDE4 inhibitor are limited ([@B6]). No effects on the cardiovascular system have been observed ([@B23]).

The first study to evaluate the efficacy of roflumilast in the treatment of AR was conducted by [@B29]. In that study, roflumilast was found to be safe and well tolerated at the same dose as that used in COPD, 500 µg once a day. Headache was the most common side effect, and was followed by nausea and dizziness in some patients. Three days after the onset of treatment, increased airflow at rhinomanometry was recorded. After 4 d of treatment, subjective improvement of the obstruction was reported by the patients. Taken together, this study provided evidence that orally administered roflumilast is an effective anti-allergy therapy in AR. No further studies have been conducted on the efficacy of roflumilast in AR ([@B15]).

Novel PDE4 Inhibitors {#s6}
=====================

The clinical development of PDE4 inhibitors has recently focused on the novel PDE4 inhibitor CHF6001. It has been designed for intranasal delivery which allows CHF6001 to reach therapeutic concentration in the lung and reduce systemic side effects. CHF6001 administered twice a day decreases the levels of various inflammatory biomarkers in the sputum and reduces systematic adverse reactions in COPD patients ([@B32]). It seems to be well tolerated and able to reduce the allergen challenge response in asthmatic patients ([@B31]). CHF6001 is characterized by anti-inflammatory effects through the ability to reduce the activation of innate immune cells. This substance can effectively inhibit the release of TNF-α and oxidative burst.

GSK256066, another PDE4 inhibitor for intranasal use, was administered for 7 d in a double blind, placebo controlled, cross-over study. It significantly reduced the response to allergen challenge and attenuated the decrease in lung function in patients with asthma. Moreover, it is associated with low systemic effects ([@B30]). A clinical trial on cilomilast was disappointing because strong side effects such as nausea, vomiting, headache, and diarrhea were observed ([@B24]).

Therapeutic Use of PDE4 Inhibitors in Disorders Other Than AR {#s7}
=============================================================

PDE4 inhibitors can also be used for the treatment of Th1-mediated autoimmune diseases. They inhibit T-cell proliferation. Compared to GCs, the activity and effects of PDE4 inhibitors appear to be better in patients with a predisposition to atopic reactions ([@B29]). For skin diseases, apremilast, a selective PDE4 inhibitor administered orally, is approved for the treatment of adults with plaque psoriasis and psoriatic arthritis in Japan and United States ([@B18]).

In a prospective study, genetic analysis revealed significant differences between the *PDE4D* (rs1588265) gene in patients with no history of nasal polyposis (a type of AR) and patients with nasal polyposis, indicating the potential of using a PD4 inhibitor for the management of patients with nasal polyposis ([@B1]).

The effects of PDE inhibitors on ciliary beating frequency in rabbit maxillary sinus and trachea have been also investigated. The authors compared rolipram, a cAMP-specific PDE4 inhibitor with bronchodilator and anti-inflammatory activities with milrinone, a cGMP-specific PDE3 inhibitor with good bronchodilator activity but weak anti-inflammatory activity and zaprinast, a cGMP-specific PDE5 inhibitor with weak bronchodilator effects. All of them stimulated ciliary beating frequency in explants from the maxillary sinus as well as from the tracheal mucosa ([@B4]).

Conclusions {#s8}
===========

AR is a common health problem with a rising incidence. Inadequate treatment may cause chronic AR and contribute to lower respiratory tract diseases such as bronchial asthma. In general, the disease can be well controlled with adequate treatment with the exception of AR, which is not mediated by the Th2-inflammatory pathway and does not respond to current available treatment modalities such as corticosteroids and antihistamines. PDE4 inhibitors can suppress a variety of inflammatory cell functions that are known to contribute to AR. However, use of systemically delivered PDE4 inhibitors, such as roflumilast, are limited by systemic side effects. Topical treatment with inhaled PDE4 inhibitors may be a viable alternative to increase tolerability and determine the maximum therapeutic potential of PDE4 inhibition in AR.
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